Network Pharmacology-Based Strategy for Predicting Therapy Targets of Citri Reticulatae Pericarpium on Myocardial Hypertrophy
Guardado en:
| Publicado en: | BioMed Research International vol. 2022 (2022) |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , |
| Publicado: |
John Wiley & Sons, Inc.
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 2638546852 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2314-6133 | ||
| 022 | |a 2314-6141 | ||
| 022 | |a 1110-7243 | ||
| 022 | |a 1110-7251 | ||
| 024 | 7 | |a 10.1155/2022/4293265 |2 doi | |
| 035 | |a 2638546852 | ||
| 045 | 2 | |b d20220101 |b d20221231 | |
| 084 | |a 131331 |2 nlm | ||
| 100 | 1 | |a Jiang, Shisheng |u Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China | |
| 245 | 1 | |a Network Pharmacology-Based Strategy for Predicting Therapy Targets of Citri Reticulatae Pericarpium on Myocardial Hypertrophy | |
| 260 | |b John Wiley & Sons, Inc. |c 2022 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Objective. Through a network pharmacology method, we screened the main active compounds of Citri Reticulatae Pericarpium (CRP), constructed a drug-ingredient-disease-target network, explored the molecular mechanism of its treatment of myocardial hypertrophy, and validated it by using molecular biology approach. Methods. Traditional Chinese Medicine Systems Pharmacology (TCMSP) and GeneCards were utilised to collect the effective component in CRP and the targets of CRP and myocardial hypertrophy. The STRING database constructed the protein interaction network. The drug-ingredient-disease-target network was outlined by the Cytoscape 3.9.0 software. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted using the Metascape database. Real-time PCR (RT-PCR) and Western blotting were utilised to determine the mRNA and protein level of the critical targets of CRP therapy for myocardial hypertrophy. Results. We found that five practical components of CRP exerted therapeutic effects on myocardial hypertrophy by modulating 41 targets. Further analysis revealed that naringenin was the essential active compound in CRP that regulated myocardial hypertrophy. In addition, we showed that the active compounds of CRP might exert antihypertrophy effects via regulating essential target proteins such as AKT1-, MAPK3-, PPARA-, PPARG-, and ESR1-mediated signaling pathways such as cell proliferation, nuclear receptor activation, and oxidative stress. The molecular biology experiments demonstrated that naringenin inhibited the mRNA level of NPPA and NPPB induced by Ang II and regulated related targets such as AKT1, MAPK3, PPARA, PPARG, and ESR1. Conclusion. CRP could inhibit myocardial hypertrophy through multitarget and multiapproach. | |
| 610 | 4 | |a Citri | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a China | |
| 653 | |a Databases | ||
| 653 | |a Hypertrophy | ||
| 653 | |a Pharmacology | ||
| 653 | |a Software | ||
| 653 | |a Encyclopedias | ||
| 653 | |a Traditional Chinese medicine | ||
| 653 | |a Ingredients | ||
| 653 | |a Genomes | ||
| 653 | |a Cell proliferation | ||
| 653 | |a Peroxisome proliferator-activated receptors | ||
| 653 | |a Polymerase chain reaction | ||
| 653 | |a Receptor mechanisms | ||
| 653 | |a ESR1 protein | ||
| 653 | |a Genes | ||
| 653 | |a Molecular biology | ||
| 653 | |a Atherosclerosis | ||
| 653 | |a Kinases | ||
| 653 | |a Perl | ||
| 653 | |a Cell activation | ||
| 653 | |a Statistical analysis | ||
| 653 | |a Proteins | ||
| 653 | |a Programming languages | ||
| 653 | |a Computer programs | ||
| 653 | |a Oxidative stress | ||
| 653 | |a Computer programming | ||
| 653 | |a mRNA | ||
| 653 | |a Angiotensin II | ||
| 653 | |a Cardiomyocytes | ||
| 653 | |a Flavonoids | ||
| 653 | |a Cardiovascular disease | ||
| 653 | |a Molecular weight | ||
| 653 | |a System effectiveness | ||
| 653 | |a Naringenin | ||
| 653 | |a Herbal medicine | ||
| 653 | |a AKT1 protein | ||
| 653 | |a Biology | ||
| 653 | |a Western blotting | ||
| 653 | |a Biomedical research | ||
| 700 | 1 | |a Huang, Chaoming |u Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China | |
| 700 | 1 | |a Wang, Shulin |u The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Guangzhou Medical University, Guangzhou, Qingyuan 511500, China | |
| 700 | 1 | |a Huang, Biyun |u Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China | |
| 700 | 1 | |a Wu, Dan |u Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China | |
| 700 | 1 | |a Zheng, Guodong |u Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China | |
| 700 | 1 | |a Cai, Yi |u Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China; The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Guangzhou Medical University, Guangzhou, Qingyuan 511500, China | |
| 773 | 0 | |t BioMed Research International |g vol. 2022 (2022) | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/2638546852/abstract/embedded/H09TXR3UUZB2ISDL?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/2638546852/fulltext/embedded/H09TXR3UUZB2ISDL?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/2638546852/fulltextPDF/embedded/H09TXR3UUZB2ISDL?source=fedsrch |